This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Shimada H, Nabeya Y, Okazumi S, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.
Okamura A, Matsuda S, Mayanagi S, et al. Clinical significance of pretherapeutic serum squamous cell carcinoma antigen level in patients with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08716-y.
Yokota T, Kato K, Hamamoto Y, et al. A 3–year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27:460–7.
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.
Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.
None declared conflicts of interests for this study. Conflicts of interests outside this work are as follows; Yuko Kitagawa received research funding from Taiho Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Daiichi Sankyo, Merck Serono, Asahi Kasei, EA Pharma, Otsuka Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical Factory, Shionogi, Kaken Pharmaceutical, Kowa Pharmaceutical, Astellas Pharma, Medicon, Dainippon Sumitomo Pharma, Taisho Toyama Pharmaceutical, Kyouwa Hakkou Kirin, Pfizer Japan, Ono Pharmaceutical, Nihon Pharmaceutical, Japan Blood Products Organization, Medtronic Japan, Sanofi K.K. grants from Eisai, Tsumura, KCI Licensing, Abbott Japan, and Fujifilm Toyama Chemical.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Okamura, A., Matsuda, S., Kawakubo, H. et al. ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Ann Surg Oncol (2020). https://doi.org/10.1245/s10434-020-08772-4